Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Pivotal Data Refine Treatment Strategies in Hodgkin Lymphoma and Follicular Lymphoma

February 27th 2019

Leo I. Gordon, MD, discussed these recent updates in Hodgkin lymphoma and non–Hodgkin lymphoma and pointed to research on the horizon.

FDA Grants Lenalidomide/Rituximab Priority Review for Indolent Non-Hodgkin Lymphoma

February 27th 2019

The FDA has granted a priority review designation to a supplemental new drug application for the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

FDA Grants Polatuzumab Vedotin Priority Review for DLBCL

February 19th 2019

The FDA has granted a priority review designation to polatuzumab vedotin for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

FDA Grants Umbralisib Breakthrough Designation for Marginal Zone Lymphoma

January 22nd 2019

The FDA has granted umbralisib (TGR-1202) a breakthrough therapy designation for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20 regimen.

Cause for Optimism in Follicular Lymphoma Treatment

January 19th 2019

Emerging Therapies and Combinations

January 19th 2019

Immunotherapeutic Agents Against Follicular Lymphoma

January 19th 2019

Potential of R2 Regimen in Treating Follicular Lymphoma

January 19th 2019

Strategies for Therapeutic Sequencing Agents

January 19th 2019

Long-Term Efficacy and Safety of Copanlisib

January 19th 2019

Use of PI3K Inhibitors in Relapsed Follicular Lymphoma

January 19th 2019

Third-Line Treatments and Transplantation

January 19th 2019

Treating Relapsed or Refractory Follicular Lymphoma

January 19th 2019

Maintenance Therapy and MRD Testing in Follicular Lymphoma

January 19th 2019

Treatment Options for High-Risk Follicular Lymphoma Cases

January 19th 2019

Up-Front Therapy in Follicular Lymphoma

January 19th 2019

Risk Assessment in Follicular Lymphoma

January 19th 2019

Diagnosis and Prognosis of Follicular Lymphoma

January 19th 2019

Targeting BCL-2 in Hematologic Malignancies

January 11th 2019

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

BCL-2: Mechanisms and Prevalence

January 10th 2019

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.